365 related articles for article (PubMed ID: 27089179)
1. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma.
Moore AR; Ceraudo E; Sher JJ; Guan Y; Shoushtari AN; Chang MT; Zhang JQ; Walczak EG; Kazmi MA; Taylor BS; Huber T; Chi P; Sakmar TP; Chen Y
Nat Genet; 2016 Jun; 48(6):675-80. PubMed ID: 27089179
[TBL] [Abstract][Full Text] [Related]
2. Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi.
Möller I; Murali R; Müller H; Wiesner T; Jackett LA; Scholz SL; Cosgarea I; van de Nes JA; Sucker A; Hillen U; Schilling B; Paschen A; Kutzner H; Rütten A; Böckers M; Scolyer RA; Schadendorf D; Griewank KG
Mod Pathol; 2017 Mar; 30(3):350-356. PubMed ID: 27934878
[TBL] [Abstract][Full Text] [Related]
3. Involvement of mutant and wild-type CYSLTR2 in the development and progression of uveal nevi and melanoma.
Nell RJ; Menger NV; Versluis M; Luyten GPM; Verdijk RM; Madigan MC; Jager MJ; van der Velden PA
BMC Cancer; 2021 Feb; 21(1):164. PubMed ID: 33588787
[TBL] [Abstract][Full Text] [Related]
4. Mutations of GNAQ, GNA11, SF3B1, EIF1AX, PLCB4 and CYSLTR in Uveal Melanoma in Chinese Patients.
Hou C; Xiao L; Ren X; Tang F; Guo B; Zeng W; Liang C; Yan N
Ophthalmic Res; 2020; 63(3):358-368. PubMed ID: 31614358
[TBL] [Abstract][Full Text] [Related]
5. Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling.
Ceraudo E; Horioka M; Mattheisen JM; Hitchman TD; Moore AR; Kazmi MA; Chi P; Chen Y; Sakmar TP; Huber T
J Biol Chem; 2021; 296():100163. PubMed ID: 33288675
[TBL] [Abstract][Full Text] [Related]
6. Uveal Melanomas Harbor Recurrent Activating Mutations in CYSLTR2.
Cancer Discov; 2016 Jun; 6(6):573. PubMed ID: 27150534
[TBL] [Abstract][Full Text] [Related]
7. Bioinformatics analysis of GNAQ, GNA11, BAP1, SF3B1,SRSF2, EIF1AX, PLCB4, and CYSLTR2 genes and their role in the pathogenesis of Uveal Melanoma.
Akin-Bali DF
Ophthalmic Genet; 2021 Dec; 42(6):732-743. PubMed ID: 34353217
[TBL] [Abstract][Full Text] [Related]
8. Mutations in GNA11 in uveal melanoma.
Van Raamsdonk CD; Griewank KG; Crosby MB; Garrido MC; Vemula S; Wiesner T; Obenauf AC; Wackernagel W; Green G; Bouvier N; Sozen MM; Baimukanova G; Roy R; Heguy A; Dolgalev I; Khanin R; Busam K; Speicher MR; O'Brien J; Bastian BC
N Engl J Med; 2010 Dec; 363(23):2191-9. PubMed ID: 21083380
[TBL] [Abstract][Full Text] [Related]
9. Functional characterization of uveal melanoma oncogenes.
Ma J; Weng L; Bastian BC; Chen X
Oncogene; 2021 Jan; 40(4):806-820. PubMed ID: 33262460
[TBL] [Abstract][Full Text] [Related]
10. GNAQ and GNA11 mutations in uveal melanoma.
Shoushtari AN; Carvajal RD
Melanoma Res; 2014 Dec; 24(6):525-34. PubMed ID: 25304237
[TBL] [Abstract][Full Text] [Related]
11. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4.
Johansson P; Aoude LG; Wadt K; Glasson WJ; Warrier SK; Hewitt AW; Kiilgaard JF; Heegaard S; Isaacs T; Franchina M; Ingvar C; Vermeulen T; Whitehead KJ; Schmidt CW; Palmer JM; Symmons J; Gerdes AM; Jönsson G; Hayward NK
Oncotarget; 2016 Jan; 7(4):4624-31. PubMed ID: 26683228
[TBL] [Abstract][Full Text] [Related]
12. Uveal melanoma-associated mutations in PLCβ4 are constitutively activating and promote melanocyte proliferation and tumorigenesis.
Phan HTN; Kim NH; Wei W; Tall GG; Smrcka AV
Sci Signal; 2021 Dec; 14(713):eabj4243. PubMed ID: 34905385
[TBL] [Abstract][Full Text] [Related]
13. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry.
Feng X; Degese MS; Iglesias-Bartolome R; Vaque JP; Molinolo AA; Rodrigues M; Zaidi MR; Ksander BR; Merlino G; Sodhi A; Chen Q; Gutkind JS
Cancer Cell; 2014 Jun; 25(6):831-45. PubMed ID: 24882515
[TBL] [Abstract][Full Text] [Related]
14. Research in practice: Therapeutic targeting of oncogenic GNAQ mutations in uveal melanoma.
Gaffal E
J Dtsch Dermatol Ges; 2020 Nov; 18(11):1245-1248. PubMed ID: 32954611
[TBL] [Abstract][Full Text] [Related]
15. GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma.
Moore AR; Ran L; Guan Y; Sher JJ; Hitchman TD; Zhang JQ; Hwang C; Walzak EG; Shoushtari AN; Monette S; Murali R; Wiesner T; Griewank KG; Chi P; Chen Y
Cell Rep; 2018 Feb; 22(9):2455-2468. PubMed ID: 29490280
[TBL] [Abstract][Full Text] [Related]
16. Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for
Paradis JS; Acosta M; Saddawi-Konefka R; Kishore A; Gomes F; Arang N; Tiago M; Coma S; Lubrano S; Wu X; Ford K; Day CP; Merlino G; Mali P; Pachter JA; Sato T; Aplin AE; Gutkind JS
Clin Cancer Res; 2021 Jun; 27(11):3190-3200. PubMed ID: 33568347
[TBL] [Abstract][Full Text] [Related]
17. The Role of Mutation Rates of GNAQ or GNA11 in Cases of Uveal Melanoma in Japan.
Ominato J; Fukuchi T; Sato A; Yamaguchi N; Kobayashi K; Cho H; Oyama T; Ajioka Y
Appl Immunohistochem Mol Morphol; 2018 Oct; 26(9):658-663. PubMed ID: 28248732
[TBL] [Abstract][Full Text] [Related]
18. Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system.
van de Nes J; Gessi M; Sucker A; Möller I; Stiller M; Horn S; Scholz SL; Pischler C; Stadtler N; Schilling B; Zimmer L; Hillen U; Scolyer RA; Buckland ME; Lauriola L; Pietsch T; Waha A; Schadendorf D; Murali R; Griewank KG
J Neurooncol; 2016 May; 127(3):435-44. PubMed ID: 26744134
[TBL] [Abstract][Full Text] [Related]
19. Frequent and Yet Unreported GNAQ and GNA11 Mutations are Found in Uveal Melanomas.
Schneider B; Riedel K; Zhivov A; Huehns M; Zettl H; Guthoff RF; Jünemann A; Erbersdobler A; Zimpfer A
Pathol Oncol Res; 2019 Oct; 25(4):1319-1325. PubMed ID: 29209985
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma.
Slater K; Hoo PS; Buckley AM; Piulats JM; Villanueva A; Portela A; Kennedy BN
Cancer Metastasis Rev; 2018 Sep; 37(2-3):335-345. PubMed ID: 30094568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]